We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




WBC Count Could Predict Severity of COVID-19 Symptoms

By LabMedica International staff writers
Posted on 03 Feb 2025

The global health crisis caused by the SARS-CoV-2 virus continues to impact millions of people worldwide, with many experiencing persistent symptoms months after the initial diagnosis. More...

Cognitive impairment and fatigue are among the most common lingering effects, with a staggering 70% of patients suffering from cognitive impairment. Older adults, particularly women, are disproportionately affected. Despite significant advances in understanding COVID-19 since its emergence in 2020, several aspects of its impact on the human body remain unclear. While COVID-19 is primarily a respiratory disease, research has revealed widespread effects on multiple organ systems. Previous studies have identified an exaggerated immune response to COVID-19 infection. Now, a new study has shed light on a potential indicator of the most likely patients to experience severe symptoms of COVID-19 infection: leukocyte (white blood cell) count.

This study drew on data from the Women's Health Initiative, a comprehensive research project funded by the National Institutes of Health (NIH, Bethesda, MD, USA). Researchers sought to investigate pre-existing risk factors that might make older adults, particularly postmenopausal women, more susceptible to prolonged and severe symptoms. They examined the relationship between leukocyte count, a readily available clinical marker of systemic inflammation, and COVID disease outcomes. Their findings, published in the journal Menopause, suggest that leukocyte count is a reliable predictor of COVID symptom severity in postmenopausal women. This research contributes to the growing evidence that low-grade inflammation is not only an outcome of severe COVID-19 symptoms but also a potential precursor to the acute infection. Further investigation is needed, but the initial findings hold promise, as leukocyte count represents a relatively inexpensive and easily accessible clinical marker.

“As the authors highlight, post-acute sequelae of severe acute respiratory coronavirus 2 infection significantly affects quality of life, often leading to severe disability,” said Dr. Monica Christmas, associate medical director for The Menopause Society. “This effect is particularly pronounced in women, who already experience higher rates of cognitive impairment after menopause. By understanding underlying factors, we can better address these challenges and work to mitigate the cascade of symptoms that follow.”


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.